CN103239679B - Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition - Google Patents
Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition Download PDFInfo
- Publication number
- CN103239679B CN103239679B CN201310184134.9A CN201310184134A CN103239679B CN 103239679 B CN103239679 B CN 103239679B CN 201310184134 A CN201310184134 A CN 201310184134A CN 103239679 B CN103239679 B CN 103239679B
- Authority
- CN
- China
- Prior art keywords
- liver
- cirrhosis
- traditional chinese
- radix
- hepatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses Chinese patent drug half-extract tablets special for preventing and treating early and interim hepatic cirrhosis and part complications of the hepatic cirrhosis and a preparation method thereof. The traditional Chinese medicament composition consists of eleven medicaments of turtle shell, common yam rhizome, gizzard-membrane of chicken, astragalus mongholicus, salvia miltiorrhiza, liquorice, zedoary, pseudo-ginseng, poria cocos, orange peel and cimicifuga foetida. The dosage of the medicament is low; and the overall medicament property is mild. The traditional Chinese medicament composition has the advantages of softening a hard lump, removing stasis, eliminating swell, releasing fatigue, remarkably improving liver functions, and effectively preventing, treating and inhibiting hepatic fatty degeneration, hepatic fibrosis and fibrosis cirrhosis.
Description
Technical field
the invention belongs to technical field of Chinese medicines, be specifically related to prevent, treatment early, the Chinese patent medicine semi-extract tablets agent of middle cirrhosis and preparation method thereof technical field.[also known as clear woods liver-protecting tablet].
Background technology
liver cirrhosis (hepatic cirrhosis) is clinical common chronic progressive external hepatopathy, the diffusivity hepatic injury that long-term or repeated action is formed by one or more causes of disease.I type and type III collagen protein showed increased during liver cirrhosis and calm in lobule everywhere.Along with the continuous deposition of collagen protein in sinusoid, fenestra of endothelial cell obviously reduces, and makes sinus hepaticus develop into blood capillary gradually, causes mass exchange obstacle between blood and hepatocyte.A large amount of collagens of liver cirrhosis come from the fat-storing cell (Ito cell) in sinusoid (Disse chamber), and this hyperplasia enlivens, and can change into fibroblast like cell.Though when the fibrous tissue of initial stage hypertrophy forms little bar rope but is not yet connected to each other formation interval and reconstructs lobules of liver structure, be called hepatic fibrosis.If continue progress, the fibrous septum at the places such as centrilobular district and portal area will be connected to each other, and make lobules of liver structure and blood circulation reconstruct and form liver cirrhosis.In China, great majority are posthepatitic cirrhosis, and small part is alcoholic cirrhosis and Cirrhosis In Schistosomiasis.
the existing Patients with Chronic HBV Infection of China about 9,300 ten thousand people, wherein has symptom to need the activeness hepatitis B patient for the treatment of to be about more than 2,000 ten thousand.Current HBV carrier rate is 7.18%, and wherein about 1/3rd have hepatic injury repeatedly, shows as hepatitis B or the liver cirrhosis of activeness.General Symptoms: mainly contain weak, easy tired, strength dissolved.Face's pigmentation can be there is in a few patients.Chronic indigestion symptom: liver pain, loss of appetite, abdominal distention are weak or accompany constipation, diarrhoea, after tired obviously, above symptom is with the phenomenon extraordinary image of flu, even if a lot of patient has felt above symptom also can not expect oneself being liver cirrhosis clinically, so often just miss best therapic opportunity like this.Sign: the visible spider angioma of patient, liver palm, the light to moderate enlargement of liver is general without tenderness.Spleen can normally or silght enlargement.The state of an illness increases the weight of, until develop into the later stage, to involve multisystem gradually, with liver function injury and portal hypertension for main manifestations, and often occurs the severe complication such as digestive tract hemorrhage, hepatic encephalopathy, canceration.The fatty liver past is rare in China, thus also few to its understanding research.But there is the trend increased sharply in recent years, and become one of hepatic fibrosis and the important cercinoma prophase pathologic change of liver cirrhosis.
doctor trained in Western medicine is just suited the medicine to the illness to liver cirrhosis, and maintaining treatment, can not control cirrhosis progress.In recent years, motherland's medical science traditional Chinese medical science is now let a hundred schools contend, and with different schemes treatment liver cirrhosis, purport is all based on blood circulation promoting and dispersing pathogen accumulation, and some effect of part, all shows imperfection.First the traditional Chinese medical science stresses the theory of " preventive treatment of disease, prevention of diseae "; Moreover or do not make good use of the sick purport for the treatment of the liver: " knowing that liver is disease, in the ban tonifying the spleen "; Be ignorant of the theory of Chinese medical science of " liver body is the moon, with being sun "; Medicine is various, brings and the reaction of exacerbates chronic indigestion symptom to patient; Blood circulation promoting and dispersing pathogen accumulation medicine is too many, to digestive tract hemorrhage, spider angioma, liver palm exacerbation of symptoms.The such as patent No. of Huanghuai University's application: CN102772737A " is used for the treatment of Fibrotic Chinese medicine composition of liver cirrhosis and preparation method thereof " square medicine by: Radix Salviae Miltiorrhizae, teata glycinis, Radix Paeoniae Rubra, Radix Ophiopogonis, the Radix Astragali, Radix Codonopsis, Radix Angelicae Sinensis, Carapax Trionycis, Rhizoma Curcumae, Radix Achyranthis Bidentatae, Rhizoma Dioscoreae, Rhizoma Polygoni Cuspidati, Hedyotidis Diffusae, Fructus Amomi and Radix Glycyrrhizae Preparata etc. form, one, prescription, dosage form are various, are not suitable for batch production; Its two, object is exactly blood circulation promoting and dispersing pathogen accumulation is main, and blood circulation promoting medicine is more, its result have increase the weight of digestive tract hemorrhage, spider angioma, liver palm are may.
Summary of the invention
the present invention altogether by: ten Herba indigoferae Pseudotinctoriae such as Carapax Trionycis Rhizoma dioscoreae Endothelium Corneum Gigeriae Galli milkvitch-red sage Radix Glycyrrhizae Rhizoma Curcumae Radix Notoginseng Poria Pericarpium Citri tangerinae Rhizoma Cimicifugae form.Medication is less, and preparation is single, is applicable to batch production, overall mild in medicine property and, achieve object that is long-term and drug prophylaxis; Medication: the drugs strengthening spleens such as Rhizoma dioscoreae, Endothelium Corneum Gigeriae Galli, Poria, Pericarpium Citri tangerinae, achieve the object of " knowing that liver is disease, in the ban tonifying the spleen " and relieve chronic indigestion symptom; Medication: Rhizoma Cimicifugae ascending up spleen-Qi and Yang, Pericarpium Citri tangerinae depressed liver-energy dispersing and QI regulating, achieves the object of " liver body is the moon, with being sun "; Medication: Radix Notoginseng " not removing blood stasis of invigorating blood circulation, hemostasis does not stay the stasis of blood " achieves the object avoiding digestive tract hemorrhage, spider angioma, liver palm exacerbation of symptoms.
technical solution of the present invention: pharmaceutical raw material medicine mass ratio is in Carapax Trionycis: Rhizoma dioscoreae: Endothelium Corneum Gigeriae Galli: the Radix Astragali: Radix Salviae Miltiorrhizae: Radix Glycyrrhizae: Rhizoma Curcumae: Radix Notoginseng: Poria: Pericarpium Citri tangerinae: Rhizoma Cimicifugae is the ratio composition of 50:90:18:30:30:10:18:9:45:15:9, wherein Carapax Trionycis, Rhizoma dioscoreae, the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Glycyrrhizae, Rhizoma Curcumae, Poria, Pericarpium Citri tangerinae, Rhizoma Cimicifugae is creme medicine, Endothelium Corneum Gigeriae Galli, Radix Notoginseng is powder medicine, wherein require that Carapax Trionycis is that (get sand puts in pot processed with vinegar, after making popular with high heat, add clean Carapax Trionycis, constantly stir, scald to surface faint yellow, take out, sieve removes sand, quench in vinegar, dry, used time smashs to pieces.Every Carapax Trionycis 100kg, uses vinegar 20kg), require that Radix Notoginseng is (Araliaceae) spring Radix Notoginseng, require that Endothelium Corneum Gigeriae Galli is that vinegar fries (Endothelium Corneum Gigeriae Galli and vinegar consumption 100:10, only fried by the Endothelium Corneum Gigeriae Galli slow fire made and deepen to surface color, spray vinegar, treats that vinegar is by complete inspiration Endothelium Corneum Gigeriae Galli).(get Rhizoma Curcumae sheet, add quantitative vinegar and mix thoroughly, slightly vexed, after vinegar is sucked, after putting parch container, with slow fire heating, fry to micro-yellow, slightly during focal spot, taking-up cools processed with vinegar Rhizoma Curcumae, and sieve removes chip.The every 100kg of Rhizoma Curcumae, uses rice vinegar 20kg).
method for making] 1. by Endothelium Corneum Gigeriae Galli, Radix Notoginseng, grinds into powder, and cross No. six sieves, obtain about 80% Endothelium Corneum Gigeriae Galli, Radix Notoginseng powder, separately put for subsequent use.
2. get creme medicine, put in decoction pot, add six times of water boils 30 minutes, with No. six sievings, medicinal residues add 4 times of water boils 30 minutes again, and with No. six sievings, merging filtrate, straight fire is concentrated into former total amount 1/6 magma.
3. according to magma volume, add ethanol, make alcohol content reach 70%, cold preservation leaves standstill more than 24 hours.
4. siphon supernatant, subnatant sucking filtration, merges, and after centrifugal method removing suspension impurity, medicinal liquid decompression recycling ethanol, to small size, moves in evaporating dish, and in water-bath, concentrated density is the extractum of 1.2% ~ 1.3%.
5. by powder medicine mix homogeneously, add hot dipping cream and stir rapidly.Make soft material, in the upper extrusion granulator of No. two sieves (25 order), granule is 60 ~ 70 DEG C of oven dry in baking oven.
6. granule water content, multiplex infrared ray quick moisture apparatus, general control about 5%, one-step palletizing below 80 DEG C.Upper granule adds 0.5% magnesium stearate, tabletting machine.
7. sterilizing: generally 30W uviol lamp one in 6-15m3 space, lamp is apart from 2.5 ~ 3 meters, ground, and indoor relative humidity remains on 45% ~ 60%, between temperature 10 ~ 55 DEG C.Tablet places about 10 minutes.
8. quality examination.
9. pack.
function cures mainly] hard masses softening and resolving, relieving distension is recovered from fatigue.For preventing, treating the treatment of morning, middle cirrhosis.
usage and dosage] oral, preventive dose 3-5 sheet, early, evening is each once.Therapeutic dose 4-6 sheet, three times on the one.Preventive dose can 3 months courses for the treatment of.Therapeutic dose is a course for the treatment of in 6 months, or follows the doctor's advice.
beneficial effect: invention achieves prescription medicine fewer but better, saving resource; Preparation is simple, is easy to improve precision; Effect is remarkable; There is the effect of prevention early stage liver cirrhosis.
carapax Trionycis: through animal liver fibrosis model therapeutic test result, display has obvious blocking effect in early days to hepatic fibrosis, and have suppression fat-storing cell propagation, reduce collagen protein synthesis, reduce collagen protein in Disse chamber excess deposition, and dissolve and absorb established fibrosis effect, also effectively can suppress the expression of hepatic fibrosis a2 (I) mRNA.Experiment also shows, and improves Phagocytosis By The Peritoneal Macrophages In Mice effect.
rhizoma dioscoreae occurs containing selenium-fall enzyme antiinflammatory, protection hepatocyte, prevention liver cirrhosis, hepatocarcinoma.
endothelium Corneum Gigeriae Galli experiment in vitro, Endothelium Corneum Gigeriae Galli has the effect of inhibition tumor cell.
the Radix Astragali Radix Astragali can promote that the protein of serum and liver upgrades the Radix Astragali and can prevent hepatic glycogen from reducing.
but Radix Salviae Miltiorrhizae has good role of correcting Radix Salviae Miltiorrhizae liver regeneration degree, mitosis figures index, AFP recall rate all to increase to Liver Microcirculation, illustrate that Radix Salviae Miltiorrhizae has the effect promoting liver regeneration.Obviously can reduce collagen content and have DNA synthesis when promoting liver fiber re-absorbed effect can promote liver regeneration and cell division breeding; there is the rising that certain promotion liver regeneration effect makes plasma fibronectin (PFN) level; thus improve phagocytic function and the OA of its netted interior layer system; prevent the immunologic injury of liver, reach the effect of protection hepatocyte and promotion liver cell regeneration.
glycyrrhizin in Radix Glycyrrhizae obviously can suppress the precollagenous synthesis of I, type III, reduces serum aminotransferase levels at commencement and hepatic steatosis and fibrosis, liver kernel factor active is declined and close with normal group.
rhizoma Curcumae has and alleviates hepatocellular degeneration, necrosis, recovers hepatocyte structure, function, reduces proliferation of fibrous tissue, stops fibrosis development effect.
radix Notoginseng 1. scavenging activated oxygen, anti peroxidation of lipid damage hepatocyte.2. alleviate hepatocyte injury and inflammatory reaction, suppress collage synthesis.3. suppress ECM synthesis, to liver DNA (deoxyribonucleic acid) (DNA) synthesis, there is facilitation.Panax Notoginseng saponin R h1 has obvious inhibitory action to the hepatoma carcinoma cell of cultivating.
over more than ten years, clinical treatment more than 300 example, have 11 examples to be end-age cirrhosis and Liver masses patient, all the other equal clinical cures, but some treatment times is longer, and most elder was from 2008 to 2013 years.
preparation flow:
creme medicine → decoction → thick paste
chinese medicine → mixing
powder medicine → grind into powder (crossing No. six sieves)
→ soft material processed → granule → drying processed → chemical examination moisture → granulate → lubricant → tabletting → ultraviolet disinfection → quality examination →
packaging
embodiment: clear woods liver-protecting tablet
[prescription]
content of drug is powder wherein creme wherein
carapax Trionycis (processed with vinegar) 500g 500g
rhizoma dioscoreae 900g 900g
radix Salviae Miltiorrhizae 300g 300g
rhizoma Cimicifugae 90g 90g
poria 450g 450g
pericarpium Citri tangerinae 150g 150g
processed with vinegar Rhizoma Curcumae 180g 180g
radix Astragali 300g 300g
radix Glycyrrhizae 100g 100g
endothelium Corneum Gigeriae Galli (vinegar system is dried) 180g 180g
(Araliaceae) spring Radix Notoginseng 90g 90g
[method for making], 1. by Endothelium Corneum Gigeriae Galli 180g, Radix Notoginseng 90g, grinds into powder, crosses No. six sieves, takes Endothelium Corneum Gigeriae Galli 150g respectively, Radix Notoginseng 75g, separately put for subsequent use.
2. get creme medicine, put in decoction pot, add six times of water boils 30 minutes, with No. six sievings, medicinal residues add 4 times of water boils 30 minutes again, and with No. six sievings, merging filtrate, straight fire is concentrated into about 500 milliliters.
3. according to magma volume, add ethanol, make alcohol content reach 70%, cold preservation leaves standstill more than 24 hours.
4. siphon supernatant, subnatant sucking filtration, merges, and after centrifugal method removing suspension impurity, medicinal liquid decompression recycling ethanol, to small size, moves in evaporating dish, with water-bath is concentrated into density be 1.2% ~ 1.3% be about 230 grams of extractum.
5. by powder medicine mix homogeneously, add hot dipping cream and stir rapidly.Make soft material, in the upper extrusion granulator of No. two sieves (25 order), granule is 60 ~ 70 DEG C of oven dry in baking oven, one-step palletizing below 80 DEG C.
6. granule water content, multiplex infrared moisture Quick testing instrument, general control adds 0.5% magnesium stearate tabletting about 5%, and be total to obtain 1000, sheet weighs 0.4 ~ 0.5 gram.
7. general in 6-15m3 space 30W uviol lamp one, lamp is apart from 2.5 ~ 3 meters, ground, and indoor relative humidity remains on 45% ~ 60%, between temperature 10 ~ 55 DEG C.Tablet places about 10 minutes.
8. quality examination.
9. pack.
function cures mainly] hard masses softening and resolving, relieving distension is except weary.For preventing, treating the treatment of morning, middle cirrhosis.
usage and dosage] oral, preventive dose 3-5 sheet, early, evening is each once.Therapeutic dose 4-6 sheet, three times on the one.
attention:
1. period in a medicine diet Seem Lablab Album, Radix Raphani, Bulbus Allii, Bulbus Allii Cepae, Herba Spinaciae etc.(because containing ether oily substance in this group food, this material can produce pessimal stimulation to liver and gallbladder.）
2. ban on opium-smoking and the opium trade, wine, raw and cold food.
anemia of pregnant woman, hypertension, cardiovascular and cerebrovascular vessel chronic diseases person, take under doctor instructs.
untoward reaction: not yet find.
treatment contrast:
testing index and method: before all patient treatments, treatment half a year after detect following items
1. hepatic fibrosis index: hyaluronic acid HA, type III precollagen PCIII, IV Collagen Type VI IV-C, laminin，LN LM 2. liver function: glutamate pyruvate transaminase ALT, glutamic oxaloacetic transaminase, GOT AST, glutamyl transpeptidase GT, total bilirubin TBIL, albumin A Ib, Lysozyme, albumins/globulins ratio A/G 3. colorful ultrasonic
1. include case standard in: have chronic viral hepatitis B medical history or excessive drinking history; cardinal symptom is (weak; distention and fullness in the abdomen, complexion is black, part liver palm, spider angioma); hepatic fibrosis index increases; abnormal liver function or normal, colorful ultrasonic shows: liver diffusivity Echoenhance, inequality, granule obviously increase thick enhancing, and liver surface owes smooth; splenomegaly person, or portal vein in warp>=12mm and other meet early stage liver cirrhosis and Patients with Fatty Liver.
excluded cases standard: A. trimester of pregnancy or women breast-feeding their children, those who are allergic to this drug; B. the heart, brain, kidney, hypertension and disease of hematopoietic system and mental disease person is merged; C. allly do not meet inclusive criteria, not by regulation medication, the disease patient of curative effect or safety cannot be judged.D. the schistosomicide medical history person that causes liver cirrhosis (because obtaining without clinical case).
efficacy assessment standard:
effective: cardinal symptom (weak, distention and fullness in the abdomen, complexion is black, part liver palm, spider angioma) disappears, liver function recovery is normal, the obvious descender of hepatic fibrosis index.Colorful ultrasonic: warp≤12mm in portal vein, liver surface is tending towards smooth, and echo graininess is tending towards even.Fatty liver disappears.
take a turn for the better: cardinal symptom disappears substantially, liver function is normal, fibrosis indices in hepatic decline to some extent.Colorful ultrasonic: warp≤14mm in portal vein, liver surface owes smooth, and echo granule obviously increases thick enhancing.Mild fatty liver.
invalid: symptom elimination is not obvious, liver function is not felt any better very worsens, very ascensionist does not fall in fibrosis.Colorful ultrasonic: warp >=14mm in portal vein, liver is rough, and echo granule slabbing strengthens.Fatty liver is unchanged or increase the weight of.
statistical procedures:
physical data:
2010-2013 years time.81 routine patients, are outpatient service illness.Wherein 60 examples, all have liver cirrhosis caused by chb disease, man 29 example, female 31 example; 8 examples, male patient, alcoholic cirrhosis; 13 examples, male patient, fatty liver.Be divided into two groups at random, treatment group: hepatitis B harden 30 examples (man 14 example, female 16 example), alcohol cirrhosis 4 example, fatty liver 7 example, 43.00 ± 8.13 years old mean age, average medical history 6.34 ± 4.78 years.Matched group: hepatitis B harden 30 examples (man 15 example, female 15 example), alcohol cirrhosis 4 example, fatty liver 6 example, 43.09 ± 8.16 years old mean age, average medical history 6.31 ± 4.68 years.
therapeutic Method:
treatment group: adopt the present invention's [clear woods liver-protecting tablet] 4-6 sheet, oral, three times on the one.
matched group: to hepatitis B liver cirrhosis, adopts lamivudine 100mg, oral, once a day.Alcohol cirrhosis, employing is kept on a diet, and adds glucuronolatone one time 2 ~ 4, oral, 3 times on the one.Fatty liver, employing is kept on a diet, and adds simvastatin 10 ~ 20mg/ day, divides three times.
upper two groups equal 3 months courses for the treatment of, statistical result after half a year.1 month course for the treatment of of fatty liver.
therapeutic outcome:
treatment group: effective 11 examples of hepatitis B liver cirrhosis, take a turn for the better 17 examples, invalid 2 examples, total effective rate 93.3%; Effective 1 example of alcohol cirrhosis, take a turn for the better 2 examples, invalid 1 example, total effective rate 75.0%; Effective 4 examples of fatty liver, take a turn for the better 2 examples, and like invalid 1 example, total effective rate is greater than 88.8%.
matched group: effective 5 examples of hepatitis B liver cirrhosis, take a turn for the better 7 examples, invalid 18 examples, total effective rate 40.0%; Effective 1 example of alcohol cirrhosis, take a turn for the better 1 example, invalid 2 examples, total effective rate 50.0%; Effective 1 example of fatty liver, take a turn for the better 2 examples, invalid 3 examples, total effective rate 50.0%.
treatment group total effective rate is apparently higher than matched group.Two groups of physical data contrast there was no significant differences, P < 0.05 has statistical significance for difference.
medical record example:
case 1
lee so-and-so, female, 62 years old, people from Xiong County, Hebei, suffer from hepatitis B for many years, within 2009, about feel July to feel run-down, appetite is not good enough, go Tianjin Hospital go to a doctor, poor effect.In May, 2010, my Out-patient Department was sought medical advice, and see darkish complexion, language is unable, slow in action, readme anorexia, weak.Simply have a medical check-up in conjunction with medical history: bilateral sclera is slight xanthochromia, stomach wall and neck portion about 10 many places spider angioma.Liver palm.Tianjin City Infectious Hospital laboratory checks: type III precollagen 156ug/L, IV Collagen Type VI 105ug/L, LN laminin 16 7ug/ml, HA hyaluronidase 179mg/L, total protein TP65g/L, ALB30g/L, globulin 35g/L, A/G ratio 0.85/1, glutamate pyruvate transaminase ALT 86/L, glutamic oxaloacetic transaminase, GOT AST 78/L, glutamyl transpeptidase GT 55/L, total bilirubin 19umol/L.Fig. 1 is patient in May, 2010 liver colorful ultrasonic figure.Colorful ultrasonic: liver section form slightly owes rule, peplos is rough, and liver parenchyma Echo heterogenicity is even, and power is not etc., granule obviously increases thick enhancing, gather in liver the low echo differed in size and in strong echo nodules, visit and the even region of lamellar Echo heterogenicity in liver, in liver, the display of biliary tract structure is still clear, liver angular vein tube wall owes smooth, thickness is owed all, and traveling is tortuous, CDFI: show liver color Doppler flow signals no abnormality seen.Gall bladder shape normal in size, wall is smooth, intracavity no abnormality seen.The thick about 3.5cm of spleen, essence echo is even.Portal vein trunk diameter 13mm.
out-patient treatment immediately, adopts the present invention's [clear woods liver-protecting tablet] a time 6, oral, three times on the one.Free of discontinuities is taken medicine after half a year, patient's spirit and QI cleaning, and language is loud and clear, and reaction is quick, sees and has rosy cheeks, ask about diet normal.Simply have a medical check-up: sclera is without xanthochromia, and stomach wall district is a surplus spider angioma only, and liver palm disappears.Tianjin City Infectious Hospital laboratory checks: type III precollagen 110ug/L, IV Collagen Type VI 65ug/L, LN LN1 27ug/ml, HA hyaluronidase 105mg/L, total protein TP75g/L, albumin A LB43g/L, globulin 32g/L, A/G ratio 1.3/1, glutamate pyruvate transaminase ALT36/L, glutamic oxaloacetic transaminase, GOT AST38/L, glutamyl transpeptidase GT25/L, total bilirubin 11umol/L.Fig. 2 is patient in November, 2010 liver colorful ultrasonic figure.Colorful ultrasonic: liver section form still can, peplos is smooth, liver parenchyma echo is slightly owed evenly, granule shows slightly and increases thick enhancing, the low echo differed in size as seen in liver and in strong echo nodules, in liver, the display of biliary tract structure is still clear, liver angular vein tube wall is tending towards smooth, thickness is uneven, and traveling is tortuous, CDFI: show liver color Doppler flow signals no abnormality seen.Gall bladder shape normal in size, wall is smooth, intracavity no abnormality seen.The thick about 3.1cm of spleen, essence echo is even, portal vein trunk diameter 12mm.
this case reaches the object of clinical cure, takes prophylactic scheme immediately, one time 4, oral, three times on the one.Serve on 3 months.Once a year.(be good with spring, summer)
case 2
[disease information]
patient, Liu so-and-so, man, 40 years old, long-term heavy drinking, fatigue and asthenia, lack of appetite.Fatty liver (moderate) is found in health check-up in 2011, at other hospital admissions, within 2012, introduces my institute through friend.
fig. 3 is patient in JIUYUE, 2012 liver colorful ultrasonic figure.B ultrasonic is pointed out: fatty liver moderate.
be diagnosed as: alcoholic fatty liver is scorching.
treatment: give the present invention's [clear woods liver-protecting tablet] treatment, one time 6, oral, three times on the one.Continue with after one month, Fig. 4 is patient in October, 2012 liver colorful ultrasonic figure, looks into B ultrasonic and shows: fatty liver (slightly)
follow up a case by regular visits to after [therapeutic effect], stable disease, non-evident sympton.
conclusion:
in sum, the present invention has hard masses softening and resolving, and relieving distension is recovered from fatigue, and drug safety significantly improves liver function, and effectively prevent, treat and suppress fatty degeneration of liver, hepatic fibrosis, sclerosis, its effect comprises: 1. suppress fat-storing cell propagation, minimizing collagen protein synthesis.2. serum aminotransferase levels at commencement and hepatic steatosis and fibrosis is reduced.3. can promote that DNA during liver regeneration synthesizes and cell division breeding, there is certain promotion liver regeneration effect.Invention achieves prescription medicine fewer but better, saving resource, preparation is simple, and be easy to improve precision, effect is remarkable.Strengthen to society and people constitution and bring enormous benefits.
Claims (3)
1. the Chinese medicine composition of a prevention, treatment liver cirrhosis, it is characterized in that: represent that following traditional Chinese medicines is made by with weight portion, Carapax Trionycis: Rhizoma dioscoreae: Endothelium Corneum Gigeriae Galli: the Radix Astragali: Radix Salviae Miltiorrhizae: Radix Glycyrrhizae: Rhizoma Curcumae: Radix Notoginseng: Poria: Pericarpium Citri tangerinae: Rhizoma Cimicifugae is 50:90:18:30:30:10:18:9:45:15:9.
2. according to claim 1 for preventing, treating the Chinese medicine composition of liver cirrhosis, it is characterized in that: Carapax Trionycis 500g, Rhizoma dioscoreae 900g, Radix Astragali 300g, Radix Salviae Miltiorrhizae 300g, Radix Glycyrrhizae 100g, Rhizoma Curcumae 180g, Poria 450g, Pericarpium Citri tangerinae 150g, Rhizoma Cimicifugae 90g are creme medicine, Endothelium Corneum Gigeriae Galli 180g, Radix Notoginseng 90g are powder medicine, mix with the powder medicine pulverized after creme medicine decocting and concentrating, granule processed is pressed into tablet.
3. according to claim 1 for preventing, treating the Chinese medicine composition of liver cirrhosis, it is characterized in that: described Chinese medicine composition dosage form is tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310184134.9A CN103239679B (en) | 2013-05-19 | 2013-05-19 | Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310184134.9A CN103239679B (en) | 2013-05-19 | 2013-05-19 | Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103239679A CN103239679A (en) | 2013-08-14 |
| CN103239679B true CN103239679B (en) | 2015-06-17 |
Family
ID=48919782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310184134.9A Expired - Fee Related CN103239679B (en) | 2013-05-19 | 2013-05-19 | Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103239679B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1554429A (en) * | 2003-12-19 | 2004-12-15 | 赵忠勇 | Medicine powder for liver and spleen diseases |
| CN101015671A (en) * | 2007-02-02 | 2007-08-15 | 姚传美 | Chinese patent drug for treating cirrhosis |
-
2013
- 2013-05-19 CN CN201310184134.9A patent/CN103239679B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1554429A (en) * | 2003-12-19 | 2004-12-15 | 赵忠勇 | Medicine powder for liver and spleen diseases |
| CN101015671A (en) * | 2007-02-02 | 2007-08-15 | 姚传美 | Chinese patent drug for treating cirrhosis |
Non-Patent Citations (2)
| Title |
|---|
| 肝炎后肝硬化中医治疗近况;吕善东;《广西中医药》;20061031;第29卷(第5期);第1-3页 * |
| 肝硬化中医辨治探微;杨佼等;《中华中医药学刊》;20120531;第30卷(第5期);第1157-1159页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103239679A (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101396543B (en) | Pure traditional Chinese medicine preparation for treating cardio-cerebrovascular disease | |
| CN102133378A (en) | Medicament for treating breast cancer | |
| Pang et al. | Innovative thoughts on treating diabetes from the perspective of traditional Chinese medicine | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN101708237B (en) | Medicinal composition used for tonifying qi and invigorating pulse, preparation method thereof and application thereof | |
| CN106236833A (en) | A kind of pharmaceutical composition treating cardiovascular and cerebrovascular disease | |
| CN103948782B (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN103768542A (en) | Medicine for treating ascites due to liver cancer and preparation method thereof | |
| CN102225190A (en) | Traditional Chinese preparation for treating chronic colitis | |
| JP2023521405A (en) | Compound medicinal preparation for treating Parkinson's disease, its production method and application | |
| CN102805844A (en) | Medicine for treating liver cancer | |
| CN109248305A (en) | A kind of Chinese medicine composition and preparation method thereof for treating liver fibrosis | |
| CN103239679B (en) | Traditional Chinese medicament composition and tablets for preventing and treating hepatic cirrhosis and preparation method for traditional Chinese medicament composition | |
| CN106334065A (en) | Edible and medicinal traditional Chinese medicine formula used for treating gynecological diseases and having beauty effect and production process | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN101987188B (en) | Biological Chinese patent drug for preventing and treating hyperlipoidemia | |
| CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites | |
| CN1814217A (en) | Chinese medicine composition for treating rheumatoid arthritis and use thereof | |
| CN115944700B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN113679757B (en) | Pharmaceutical composition for improving bladder contractility and application thereof | |
| CN106421650B (en) | A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation | |
| CN106822697B (en) | Chinese medicine for relaxing bowels, preparation using same and preparation method | |
| CN104547959A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN106668390B (en) | Traditional Chinese medicine composition for treating hyperthyroidism in early and middle stages | |
| CN101081293A (en) | Capsules preparations for preventing and treating hepatic disease by dispersing blood-stasis of portal vein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 Termination date: 20190519 |